Taylor Hoffman Wealth Management Purchases 1,202 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Taylor Hoffman Wealth Management boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 13.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,117 shares of the biopharmaceutical company’s stock after acquiring an additional 1,202 shares during the period. Taylor Hoffman Wealth Management’s holdings in Bristol-Myers Squibb were worth $513,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bath Savings Trust Co grew its stake in shares of Bristol-Myers Squibb by 3.4% in the 2nd quarter. Bath Savings Trust Co now owns 17,108 shares of the biopharmaceutical company’s stock valued at $776,000 after purchasing an additional 568 shares during the period. Boltwood Capital Management grew its holdings in Bristol-Myers Squibb by 1.9% during the second quarter. Boltwood Capital Management now owns 21,626 shares of the biopharmaceutical company’s stock worth $981,000 after acquiring an additional 400 shares during the period. Thomasville National Bank grew its holdings in Bristol-Myers Squibb by 1.6% during the second quarter. Thomasville National Bank now owns 18,605 shares of the biopharmaceutical company’s stock worth $843,000 after acquiring an additional 293 shares during the period. Private Asset Management Inc. grew its holdings in Bristol-Myers Squibb by 5.5% during the second quarter. Private Asset Management Inc. now owns 129,289 shares of the biopharmaceutical company’s stock worth $5,863,000 after acquiring an additional 6,775 shares during the period. Finally, ELM Advisors LLC grew its holdings in Bristol-Myers Squibb by 5.7% during the second quarter. ELM Advisors LLC now owns 7,358 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 400 shares during the period. Hedge funds and other institutional investors own 80.40% of the company’s stock.

In other Bristol-Myers Squibb news, SVP John E. Elicker sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total value of $849,900.00. Following the completion of the sale, the senior vice president now owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the completion of the sale, the insider now directly owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by company insiders.

Several analysts have weighed in on BMY shares. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a research note on Wednesday, August 14th. TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. Wolfe Research set a $66.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. set a $62.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, September 13th. Finally, ValuEngine cut Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $56.64.

Shares of NYSE BMY traded up $0.44 during mid-day trading on Friday, reaching $58.02. The company had a trading volume of 11,418,626 shares, compared to its average volume of 12,766,524. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $58.46. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. The stock has a market cap of $91.88 billion, a PE ratio of 14.58, a P/E/G ratio of 1.31 and a beta of 0.71. The company has a 50-day moving average price of $52.90 and a two-hundred day moving average price of $48.19.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The business had revenue of $6.01 billion for the quarter, compared to the consensus estimate of $5.89 billion. During the same quarter in the previous year, the company posted $1.09 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, research analysts expect that Bristol-Myers Squibb Co will post 4.33 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a dividend of $0.41 per share. The ex-dividend date of this dividend was Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 2.83%. Bristol-Myers Squibb’s payout ratio is 41.21%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: What is an inverted yield curve?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit